Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

177 Press Releases
DateTitleCompany
09 May 13 Takeda Appoints New President for Millennium: The Takeda Oncology Company Takeda,
Published by
PharmiWeb.com
08 May 13 Takeda to Acquire Inviragen, Inc. Takeda
24 Apr 13 Takeda Submits a New Drug Application for the Fixed-Dose Combination of Azilva® and Amlodipine Besylate in Japan Takeda Pharmaceutical Company Limited
29 Mar 13 Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Mar 13 Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union Takeda Pharmaceutical Company Limited
04 Mar 13 Industry Leaders and Academic Researchers Come Together for Innovative Accelerating Cancer Cures Research Symposium Millennium: The Takeda Oncology Company,
Published by
Business Wire
24 Feb 13 Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection Affymax Inc. & Takeda Pharmaceutical Company Limited,
Published by
Business Wire
24 Jan 13 New England Journal of Medicine Publishes Pivotal Trial Data for OMONTYS® (peginesatide) Injection for Treatment of Anemia in Adult Chronic Kidney Disease Patients on Hemodialysis Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
23 Jan 13 Multiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 Jan 13 Takeda and Affymax Announce Supply Agreement for OMONTYS® (Peginesatide) Injection with DSI Renal Takeda Pharmaceuticals U.S.A. Inc. and Affymax Inc.,
Published by
Business Wire
03 Jan 13 Affymax and Takeda Announce Permanent J-Code for OMONTYS® (peginesatide) Injection is in Effect Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
11 Dec 12 Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
10 Dec 12 Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Nov 12 Takeda to Acquire Envoy Therapeutics, Inc. Envoy Therapeutics Inc. and Takeda Pharmaceutical Company Limited,
Published by
Business Wire
06 Nov 12 VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 CORRECTING and REPLACING Millennium is #1 in Boston Globe Ranking of Top Largest Employer Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 Millennium is #1 in Boston Globe Ranking of Best Large Employers Millennium: The Takeda Oncology Company,
Published by
Business Wire
02 Nov 12 Affymax and Takeda Announce Analyses from OMONTYS® (peginesatide) Injection Phase 3 Dialysis Studies Presented at 2012 American Society of Nephrology Meeting Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
01 Nov 12 Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
31 Oct 12 Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
31 Oct 12 Millennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
19 Oct 12 Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
17 Oct 12 Affymax and Takeda Announce OMONTYS® Data Presentations at the American Society of Nephrology Kidney Week 2012 Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
05 Oct 12 Takeda to Acquire LigoCyte Pharmaceuticals, Inc. Takeda
03 Oct 12 TAKEDA AND ADVINUS INITIATE MULTI-YEAR DRUG DISCOVERY COLLABORATION Takeda Pharmaceutical
01 Oct 12 Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
26 Sep 12 U.S. Food and Drug Administration Grants Priority Review Status to AMITIZA® (lubiprostone) Submission Seeking Approval for Treatment of Opioid-induced Constipation Sucampo Pharmaceuticals Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.